Boston Scientific Corporation

Official Company Name: Boston Scientific Corporation

Stock Symbol: BSX.PR.A

Stock Market: New York Stock Exchange - NYSE

Currency: United States dollar - USD

Boston Scientific Corporation Company Profile

BSX.PR.A Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+13.65%

Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

— EMA20
— SMA50
— SMA200

Boston Scientific Corporation Categories

United States Healthcare Medical Devices

Healthcare

Medical Devices

Company Description

Boston Scientific Corporation is a medical devices company. Primarily known for its drug-eluting stent which is used to open clogged arteries, Boston Scientific also designs, manufactures, and markets a number of devices for intervention and surgery in multiple medical specialties including radiology, cardiology, neurovascular intervention, endoscopy, oncology, urology and gynecology.

Boston Scientific Corporation Company Profile

BSX.PR.A Stock Data

Open	$119.70
High	$123.35
Low	$119.32
Close	$122.18
Volume	1,885,419
Previous Close	$119.35
1-Day Change	2.83
1-Year Change	14.67
Average Daily Volume	68,449
52-Week High	$128.37
52-Week Low	$98.13

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.